Trees Corporation (CANN) Fair Value 2026

CANN · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, Trees Corporation (CANN) trades at $0.02. QOC: 5.1/10. Value Trap Risk: 18/100 (SAFE). 0/13 models active.

Key Facts

Ticker
CANN
Price
$0.02
Quality Score
5.1/10
Value Trap Risk
18/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give CANN?

0 Intrinsic Value Models vs. Current Price ($0.02)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Trees Corporation (CANN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Trees Corporation currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CANN?

0 of 13 models are currently active for CANN. See which stocks rank higher →

How Does CANN Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, CANN ranks #78 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to pharmaceutical industry businesses. For Trees Corporation, metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.

Is CANN a Value Trap?

CirclFi's Value Trap algorithm assigns CANN a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Trees Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Trees Corporation scores 5.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CANN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Trees Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

IXHLIncannex Healthcare Inc.QOC 5.1APUSApimeds Pharmaceuticals US, Inc.QOC 5.0NTRRNeutra Corp.QOC 5.1HYEXHealthy Extracts Inc.QOC 4.9AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1RGCRegencell Bioscience Holdings LimitedQOC 4.8HCMHUTCHMED (China) LimitedQOC 2.7CRONCronos Group Inc.QOC 7.4SCYXSCYNEXIS, Inc.QOC 6.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: IXHL · APUS · NTRR · HYEX · AMLX · RGC · HCM · CRON · SCYX · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CANN?

7 companies across all industries closest to CANN’s Quality of Company score of 5.1/10.

CFOOChina Foods Holdings Ltd.QOC 5.1SMXTSolarMax Technology, Inc.QOC 5.1BIRDSmartbird, IncQOC 5.1PHCIPanamera Holdings CorporationQOC 5.1BNBXBNB Plus Corp.QOC 5.1BRLSBorealis Foods Inc.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CFOO · SMXT · BIRD · PHCI · BNBX · BRLS · NVDA

Where Does CANN Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CANN is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Trees Corporation’s Valuation?

What is Trees Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Trees Corporation (CANN). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CANN overvalued or undervalued right now?

At $0.02, 0 of 0 active models suggest CANN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Trees Corporation's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.1 mean for CANN?

Trees Corporation's QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CANN?

CirclFi analyzes CANN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CANN a value trap in 2026?

Trees Corporation's Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Trees Corporation (CANN) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/CANN/ · Methodology
Primary sources for this CANN valuation
  • Financial statements: Trees Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001477009) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CANN as of ; valuations recomputed .